In 2024, the FDA approved several significant psychiatric treatments, including Rejoyn, a digital therapeutic for major depressive disorder, and Cobenfy, a new drug for schizophrenia. Additionally, the FDA accepted an application for MDMA-assisted therapy for PTSD, marking a notable advancement in psychedelic-assisted treatments. 🧵